Inflammation as a cause of acute myocardial infarction in patients with myeloproliferative neoplasm
World J Cardiol. 2024 Feb 26;16(2):58-63. doi: 10.4330/wjc.v16.i2.58.ABSTRACTMyeloproliferative neoplasms (MPN) are a group of diseases characterized by the clonal proliferation of hematopoietic progenitor or stem cells. They are clinically classifiable into four main diseases: chronic myeloid leukemia, essential thrombocythemia, polycythemia vera, and primary myelofibrosis. These pathologies are closely related to cardio- and cerebrovascular diseases due to the increased risk of arterial thrombosis, the most common underlying cause of acute myocardial infarction. Recent evidence shows that the classical Virchow triad (hyp...
Source: World Journal of Cardiology - March 8, 2024 Category: Cardiology Authors: Amedeo Tirandi Elisa Schiavetta Elia Maioli Fabrizio Montecucco Luca Liberale Source Type: research
Inflammation as a cause of acute myocardial infarction in patients with myeloproliferative neoplasm
World J Cardiol. 2024 Feb 26;16(2):58-63. doi: 10.4330/wjc.v16.i2.58.ABSTRACTMyeloproliferative neoplasms (MPN) are a group of diseases characterized by the clonal proliferation of hematopoietic progenitor or stem cells. They are clinically classifiable into four main diseases: chronic myeloid leukemia, essential thrombocythemia, polycythemia vera, and primary myelofibrosis. These pathologies are closely related to cardio- and cerebrovascular diseases due to the increased risk of arterial thrombosis, the most common underlying cause of acute myocardial infarction. Recent evidence shows that the classical Virchow triad (hyp...
Source: World Journal of Cardiology - March 8, 2024 Category: Cardiology Authors: Amedeo Tirandi Elisa Schiavetta Elia Maioli Fabrizio Montecucco Luca Liberale Source Type: research
Inflammation as a cause of acute myocardial infarction in patients with myeloproliferative neoplasm
World J Cardiol. 2024 Feb 26;16(2):58-63. doi: 10.4330/wjc.v16.i2.58.ABSTRACTMyeloproliferative neoplasms (MPN) are a group of diseases characterized by the clonal proliferation of hematopoietic progenitor or stem cells. They are clinically classifiable into four main diseases: chronic myeloid leukemia, essential thrombocythemia, polycythemia vera, and primary myelofibrosis. These pathologies are closely related to cardio- and cerebrovascular diseases due to the increased risk of arterial thrombosis, the most common underlying cause of acute myocardial infarction. Recent evidence shows that the classical Virchow triad (hyp...
Source: World Journal of Cardiology - March 8, 2024 Category: Cardiology Authors: Amedeo Tirandi Elisa Schiavetta Elia Maioli Fabrizio Montecucco Luca Liberale Source Type: research
Inflammation as a cause of acute myocardial infarction in patients with myeloproliferative neoplasm
World J Cardiol. 2024 Feb 26;16(2):58-63. doi: 10.4330/wjc.v16.i2.58.ABSTRACTMyeloproliferative neoplasms (MPN) are a group of diseases characterized by the clonal proliferation of hematopoietic progenitor or stem cells. They are clinically classifiable into four main diseases: chronic myeloid leukemia, essential thrombocythemia, polycythemia vera, and primary myelofibrosis. These pathologies are closely related to cardio- and cerebrovascular diseases due to the increased risk of arterial thrombosis, the most common underlying cause of acute myocardial infarction. Recent evidence shows that the classical Virchow triad (hyp...
Source: World Journal of Cardiology - March 8, 2024 Category: Cardiology Authors: Amedeo Tirandi Elisa Schiavetta Elia Maioli Fabrizio Montecucco Luca Liberale Source Type: research
Inflammation as a cause of acute myocardial infarction in patients with myeloproliferative neoplasm
World J Cardiol. 2024 Feb 26;16(2):58-63. doi: 10.4330/wjc.v16.i2.58.ABSTRACTMyeloproliferative neoplasms (MPN) are a group of diseases characterized by the clonal proliferation of hematopoietic progenitor or stem cells. They are clinically classifiable into four main diseases: chronic myeloid leukemia, essential thrombocythemia, polycythemia vera, and primary myelofibrosis. These pathologies are closely related to cardio- and cerebrovascular diseases due to the increased risk of arterial thrombosis, the most common underlying cause of acute myocardial infarction. Recent evidence shows that the classical Virchow triad (hyp...
Source: World Journal of Cardiology - March 8, 2024 Category: Cardiology Authors: Amedeo Tirandi Elisa Schiavetta Elia Maioli Fabrizio Montecucco Luca Liberale Source Type: research
Inflammation as a cause of acute myocardial infarction in patients with myeloproliferative neoplasm
World J Cardiol. 2024 Feb 26;16(2):58-63. doi: 10.4330/wjc.v16.i2.58.ABSTRACTMyeloproliferative neoplasms (MPN) are a group of diseases characterized by the clonal proliferation of hematopoietic progenitor or stem cells. They are clinically classifiable into four main diseases: chronic myeloid leukemia, essential thrombocythemia, polycythemia vera, and primary myelofibrosis. These pathologies are closely related to cardio- and cerebrovascular diseases due to the increased risk of arterial thrombosis, the most common underlying cause of acute myocardial infarction. Recent evidence shows that the classical Virchow triad (hyp...
Source: World Journal of Cardiology - March 8, 2024 Category: Cardiology Authors: Amedeo Tirandi Elisa Schiavetta Elia Maioli Fabrizio Montecucco Luca Liberale Source Type: research
Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary
Conclusion: This study is the first to provide insights into the characteristics, treatment patterns, and outcomes of CML patients treated with TKIs in Hungarian clinical practice between 2011 and 2019. We found slightly lower OS rates compared to other European countries, however, there was a statistically significant improvement in 4-year OS during the study period. The management of CML was in line with international guidelines and recommendations.PMID:38444749 | PMC:PMC10913892 | DOI:10.3389/pore.2024.1611497 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - March 6, 2024 Category: Pathology Authors: Peter Batar Hussain Alizadeh Gyorgy Rokszin Zsolt Abonyi-Toth Judit Demeter Source Type: research
Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary
Conclusion: This study is the first to provide insights into the characteristics, treatment patterns, and outcomes of CML patients treated with TKIs in Hungarian clinical practice between 2011 and 2019. We found slightly lower OS rates compared to other European countries, however, there was a statistically significant improvement in 4-year OS during the study period. The management of CML was in line with international guidelines and recommendations.PMID:38444749 | PMC:PMC10913892 | DOI:10.3389/pore.2024.1611497 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - March 6, 2024 Category: Pathology Authors: Peter Batar Hussain Alizadeh Gyorgy Rokszin Zsolt Abonyi-Toth Judit Demeter Source Type: research
Clinical outcomes of patients with lymphoid blastic phase of chronic myeloid leukemia treated with CAR T-cell therapy
Blood Cancer Journal, Published online: 06 March 2024; doi:10.1038/s41408-024-01020-yClinical outcomes of patients with lymphoid blastic phase of chronic myeloid leukemia treated with CAR T-cell therapy (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - March 6, 2024 Category: Hematology Authors: Yujie Liu Yuqing Tu Jinyan Xiao Yifan Shen Biqi Zhou Qiannan Yang Lei Yu Lijuan Qi Jia Chen Tianhui Liu Depei Wu Yang Xu Source Type: research
Design, synthesis and antitumor activity of 2-substituted quinazoline-4-amine derivatives
In this study, a series of new N-arylquinazoline-4-amine analogs were designed and synthesized based on structure optimization of quinazoline. The structures of the thirty-two newly synthesized compounds were confirmed by 1H NMR, 13C NMR and ESI-MS. The anticancer activity in vitro against chronic myeloid leukemia cells (K562), non-small cell lung cancer cells (A549), human prostate cancer cells (PC3), and cervical cancer cells (HeLa) of the target compounds was evaluated. Among them, the inhibition ratio of compounds 17d, 18a, 18b, 11 and 23a against four cancer cells at 5 μM concentration were more than 50 %. The IC50 v...
Source: Cancer Control - March 5, 2024 Category: Cancer & Oncology Authors: Menghan Wang Jia Yu Xinyi Huang Gang Yu Qi Liang Sha Cheng Xueling Meng Guangcan Xu Huimin Li Heng Luo Bixue Xu Source Type: research
Design, synthesis and antitumor activity of 2-substituted quinazoline-4-amine derivatives
In this study, a series of new N-arylquinazoline-4-amine analogs were designed and synthesized based on structure optimization of quinazoline. The structures of the thirty-two newly synthesized compounds were confirmed by 1H NMR, 13C NMR and ESI-MS. The anticancer activity in vitro against chronic myeloid leukemia cells (K562), non-small cell lung cancer cells (A549), human prostate cancer cells (PC3), and cervical cancer cells (HeLa) of the target compounds was evaluated. Among them, the inhibition ratio of compounds 17d, 18a, 18b, 11 and 23a against four cancer cells at 5 μM concentration were more than 50 %. The IC50 v...
Source: Bioorganic and Medicinal Chemistry - March 5, 2024 Category: Chemistry Authors: Menghan Wang Jia Yu Xinyi Huang Gang Yu Qi Liang Sha Cheng Xueling Meng Guangcan Xu Huimin Li Heng Luo Bixue Xu Source Type: research
Design, synthesis and antitumor activity of 2-substituted quinazoline-4-amine derivatives
In this study, a series of new N-arylquinazoline-4-amine analogs were designed and synthesized based on structure optimization of quinazoline. The structures of the thirty-two newly synthesized compounds were confirmed by 1H NMR, 13C NMR and ESI-MS. The anticancer activity in vitro against chronic myeloid leukemia cells (K562), non-small cell lung cancer cells (A549), human prostate cancer cells (PC3), and cervical cancer cells (HeLa) of the target compounds was evaluated. Among them, the inhibition ratio of compounds 17d, 18a, 18b, 11 and 23a against four cancer cells at 5 μM concentration were more than 50 %. The IC50 v...
Source: Bioorganic and Medicinal Chemistry - March 5, 2024 Category: Chemistry Authors: Menghan Wang Jia Yu Xinyi Huang Gang Yu Qi Liang Sha Cheng Xueling Meng Guangcan Xu Huimin Li Heng Luo Bixue Xu Source Type: research
The potential of circHIPK3 as a biomarker in chronic myeloid leukemia
Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by leukocytosis and left shift. The primary molecular alteration is the BCR::ABL1, chimeric oncoprotein with tyrosine kinase activity, responsible for the initial oncogenesis of the disease. Therapy of CML was revolutionized with the advent of tyrosine kinase inhibitors, but it is still not considered curative and may present resistance and serious adverse effects. Discoveries in CML inaugurated a new era in cancer treatment and despite all the advances, a new biomarker is needed to detect resistance and adverse effects. Circular RNAs (circRNAs) ...
Source: Frontiers in Oncology - March 5, 2024 Category: Cancer & Oncology Source Type: research
Predictive performance of population pharmacokinetic models of imatinib in chronic myeloid leukemia patients
ConclusionMenon et al. model was able to predict well for our clinical data where it had the relative mean prediction error percentage ≤ 20%, relative median absolute prediction error ≤ 30% and relative root mean square error close to zero. Based on this final model, we proposed a dosing nomogram for various weight groups, which could potentially help to maintain the trough concentrations in the therapeutic range. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - March 5, 2024 Category: Cancer & Oncology Source Type: research
Gene expression profiling on CML patients with Philadelphia translocation
CONCLUSIONS: The results demonstrate a correlation between signaling pathways and the development of treatment resistance in patients with CML. These pathways exhibited enhanced efficacy in transmitting signals downstream of the TKI target, BCR-ABL. Several target genes require additional validation in a more extensive cohort study to verify their correlation with TKI resistance. The present research highlights that many BCR-ABL-independent pathways may be correlated with resistance, thus enhancing the prospective therapy options for patients with CML.PMID:38436167 | DOI:10.26355/eurrev_202402_35455 (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - March 4, 2024 Category: Drugs & Pharmacology Authors: H Alkhatabi S Aldahlawi M S Hazzazi R Alsolami A Elaimi M N Almashjary R Alserihi H A Alkhatabi M E Alquthami Y M Daous S Bahashwan E B Yasin A Barefah F Alsayes Source Type: research
